Molecular targeting of liposomal nanoparticles to tumor microenvironment

International Journal of Nanomedicine

Volumn 8, Issue , 2012, Pages 61-71

  Zhao, Gang ^a,b   Leticia Rodriguez, B ^b  

^a SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG FIRST MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

Cationic liposomes; Endothelium; Ligand or antibody mediated targeting; Neovasculature; Tumor microenvironment; Tumor associated macrophages

Indexed keywords

1 [2 [(9 OCTADECENOYLOXY)] 2[8] HEPTADECENYL] 3 (HYDROXYETHYL)IMIDAZOLIUM CHLORIDE; 1,2 DIOLEOYL 3 TRIMETHYLAMMONIOPROPANE; ANTINEOPLASTIC AGENT; ARGINYLGLYCYLASPARTIC ACID; CD163 ANTIGEN; CLODRONIC ACID; CYTARABINE; DIPALMITOYLPHOSPHATIDYLCHOLINE; DISTEAROYLPHOSPHATIDYLCHOLINE; DISTEAROYLPHOSPHATIDYLETHANOLAMINE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 2; HYDROGENATED SOYBEAN PHOSPHATIDYLCHOLINE; LIPOPLEX; LIPOSOME; MACROGOL; MACROGOL 2000; MICROSOMAL AMINOPEPTIDASE; N ACETYLPROLYLHISTIDYLSERYLCYSTEINYLASPARAGINE AMIDE; NANOPARTICLE; PACLITAXEL; PLASMID DNA; PLATELET DERIVED GROWTH FACTOR; RETINOIC ACID; SMALL INTERFERING RNA; STEAROYL GLYCYLPROLYLLEUCYLPROLYLLEUCYLARGININE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; VERY LATE ACTIVATION ANTIGEN 5;

ADVANCED CANCER; CELL GROWTH; DRUG ACCUMULATION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG TARGETING; DRUG TOLERABILITY; ENDOTHELIUM CELL; FIBROBLAST; HUMAN; IMMUNOCOMPETENT CELL; KAPOSI SARCOMA; LIVER METASTASIS; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; MESENCHYME CELL; MOLECULARLY TARGETED THERAPY; MULTIPLE MYELOMA; NONHUMAN; OVARY CANCER; PERICYTE; PROTEIN SECRETION; REPEATED DRUG DOSE; REVIEW; SINGLE DRUG DOSE; STROMA CELL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION; UNSPECIFIED SIDE EFFECT; VASCULAR ENDOTHELIUM;

CATIONIC LIPOSOMES; ENDOTHELIUM; LIGAND- OR ANTIBODY-MEDIATED TARGETING; NEOVASCULATURE; TUMOR MICROENVIRONMENT; TUMOR-ASSOCIATED MACROPHAGES;

ANIMALS; DRUG CARRIERS; HUMANS; LIPOSOMES; MOLECULAR TARGETED THERAPY; NANOPARTICLES; NEOPLASMS; TUMOR MICROENVIRONMENT;

EID: 84872300769     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S37859     Document Type: Review

References (101)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69-90.
2. De Palma M, Lewis CE. Cancer: Macrophages limit chemotherapy. Nature. 2011;472(7343):303-304.
3. Arias JL. Drug targeting strategies in cancer treatment: an overview. Mini Rev Med Chem. 2011;11(1):1-17.
4. Gottesman MM. Mechanisms of cancer drug resistance. Annu Rev Med. 2002;53:615-627.
5. Bindra RS, Glazer PM. Genetic instability and the tumor microenvironment: towards the concept of microenvironment-induced mutagenesis. Mutat Res. 2005;569(1-2):75-85.
6. Reynolds TY, Rockwell S, Glazer PM. Genetic instability induced by the tumor microenvironment. Cancer Res. 1996;56(24):5754-5757.
7. Hida K, Kawamoto T, Ohga N, Akiyama K, Hida Y, Shindoh M. Altered angiogenesis in the tumor microenvironment. Pathol Int. 2011;61(11):630-637.
8. Wojtkowiak JW, Verduzco D, Schramm KJ, Gillies RJ. Drug resistance and cellular adaptation to tumor acidic pH microenvironment. Mol Pharm. 2011;8(6):2032-2038.
9. Liotta LA, Kohn EC. The microenvironment of the tumour-host interface. Nature. 2001;411(6835):375-379.
10. Weber CE, Kuo PC. The tumor microenvironment. Surg Oncol. 2011;21(3):172-177.
11. Ungefroren H, Sebens S, Seidl D, Lehnert H, Hass R. Interaction of tumor cells with the microenvironment. Cell Commun Signal. 2011;9:18.
12. Li RJ, Ying X, Zhang Y, et al. All-trans retinoic acid stealth liposomes prevent the relapse of breast cancer arising from the cancer stem cells. J Control Release. 2011;149(3):281-291.
13. Kerbel RS. Tumor angiogenesis. N Engl J Med. 2008;358(19): 2039-2049.
14. Nagy JA, Chang SH, Dvorak AM, Dvorak HF. Why are tumour blood vessels abnormal and why is it important to know? Br J Cancer. 2009;100(6):865-869.
15. Carmeliet P. Angiogenesis in life, disease and medicine. Nature. 2005;438(7070):932-936.
16. Gerhardt H, Semb H. Pericytes: gatekeepers in tumour cell metastasis? J Mol Med (Berl). 2008;86(2):135-144.
17. Dvorak HF, Weaver VM, Tlsty TD, Bergers G. Tumor microenvironment and progression. J Surg Oncol. 2011;103(6):468-474.
18. Avraamides CJ, Garmy-Susini B, Varner JA. Integrins in angiogenesis and lymphangiogenesis. Nat Rev Cancer. 2008;8(8):604-617.
19. Nagy JA, Dvorak AM, Dvorak HF. VEGF-A and the induction of pathological angiogenesis. Annu Rev Pathol. 2007;2:251-275.
20. Ribatti D, Vacca A. The role of microenvironment in tumor angiogenesis. Genes Nutr. 2008;3(1):29-34.
21. de Visser KE, Eichten A, Coussens LM. Paradoxical roles of the immune system during cancer development. Nat Rev Cancer. 2006;6(1):24-37.
22. Lewis CE, Pollard JW. Distinct role of macrophages in different tumor microenvironments. Cancer Res. 2006;66(2):605-612.
23. Leek RD, Lewis CE, Whitehouse R, Greenall M, Clarke J, Harris AL. Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res. 1996;56(20): 4625-4629.
24. DeNardo DG, Andreu P, Coussens LM. Interactions between lymphocytes and myeloid cells regulate proversus anti-tumor immunity. Cancer Metastasis Rev. 2010;29(2):309-316.
25. Andreu P, Johansson M, Affara NI, et al. FcRgamma activation regulates inflammation-associated squamous carcinogenesis. Cancer Cell. 2010;17(2):121-134.
26. Allavena P, Sica A, Garlanda C, Mantovani A. The Yin-Yang of tumor-associated macrophages in neoplastic progression and immune surveillance. Immunol Rev. 2008;222:155-161.
27. Bingle L, Brown NJ, Lewis CE. The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol. 2002;196(3):254-265.
28. Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell. 2010;141(1):39-51.
29. Wai LE, Garcia JA, Martinez OM, Krams SM. Distinct roles for the NK cell-activating receptors in mediating interactions with dendritic cells and tumor cells. J Immunol. 2011;186(1):222-229.
30. Caligiuri MA. Human natural killer cells. Blood. 2008;112(3):461-469.
31. Ferrone S, Whiteside TL. Tumor microenvironment and immune escape. Surg Oncol Clin N Am. 2007;16(4):755-774.
32. Haley B, Frenkel E. Nanoparticles for drug delivery in cancer treatment. Urol Oncol. 2008;26(1):57-64.
33. Penate Medina O, Haikola M, Tahtinen M, et al. Liposomal tumor targeting in drug delivery utilizing MMP-2-and MMP-9-binding ligands. J Drug Deliv. 2011;160515.
34. Musacchio T, Torchilin VP. Recent developments in lipid-based pharmaceutical nanocarriers. Front Biosci. 2011;16:1388-1412.
35. Pérez-López ME, Curiel T, Gómez JG, Jorge M. Role of pegylated liposomal doxorubicin (Caelyx) in the treatment of relapsing ovarian cancer. Anticancer Drugs. 2007;18(5):611-617.
36. Ludwig H, Strasser-Weippl K, Schreder M, Zojer N. Advances in the treatment of hematological malignancies: current treatment approaches in multiple myeloma. Ann Oncol. 2007;18 Suppl 9:64-70.
37. Moghimi SM, Szebeni J. Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. Prog Lipid Res. 2003;42(6):463-478.
38. Guo X, Huang L. Recent advances in nonviral vectors for gene delivery. Acc Chem Res. 2012;45(7):971-979.
39. Romberg B, Hennink WE, Storm G. Sheddable coatings for long-circulating nanoparticles. Pharm Res. 2008;25(1):55-71.
40. Lasic DD. Doxorubicin in sterically stabilized liposomes. Nature. 1996;380(6574):561-562.
41. Kim IY, Kang YS, Lee DS, et al. Antitumor activity of EGFR targeted pH-sensitive immunoliposomes encapsulating gemcitabine in A549 xenograft nude mice. J Control Release. 2009;140(1):55-60.
42. Andresen TL, Jensen SS, Kaasgaard T, Jørgensen K. Triggered activation and release of liposomal prodrugs and drugs in cancer tissue by secretory phospholipase A2. Curr Drug Deliv. 2005;2(4): 353-362.
43. McLean JW, Fox EA, Baluk P, et al. Organ-specific endothelial cell uptake of cationic liposome-DNA complexes in mice. Am J Physiol. 1997;273(1 Pt 2):H387-H404.
44. Eichhorn ME, Strieth S, Krasnici S, et al. Protamine enhances uptake of cationic liposomes in angiogenic microvessels. Angiogenesis. 2004;7(2):133-141.
45. Strieth S, Eichhorn ME, Werner A, et al. Paclitaxel encapsulated in cationic liposomes increases tumor microvessel leakiness and improves therapeutic efficacy in combination with Cisplatin. Clin Cancer Res. 2008;14(14):4603-4611.
46. Strieth S, Nussbaum CF, Eichhorn ME, et al. Tumor-selective vessel occlusions by platelets after vascular targeting chemotherapy using paclitaxel encapsulated in cationic liposomes. Int J Cancer. 2008;122(2):452-460.
47. Schmitt-Sody M, Strieth S, Krasnici S, et al. Neovascular targeting therapy: paclitaxel encapsulated in cationic liposomes improves anti-tumoral efficacy. Clin Cancer Res. 2003;9(6):2335-2341.
48. Fasol U, Frost A, Büchert M, et al. Vascular and pharmacokinetic effects of EndoTAG-1 in patients with advanced cancer and liver metastasis. Ann Oncol. 2012;23(4):1030-1036.
49. Danielsen T, Rofstad EK. VEGF, bFGF and EGF in the angiogenesis of human melanoma xenografts. Int J Cancer. 1998;76(6):836-841.
50. Kwabi-Addo B, Ozen M, Ittmann M. The role of fibroblast growth factors and their receptors in prostate cancer. Endocr Relat Cancer. 2004;11(4):709-724.
51. Wang X, Deng L, Chen X, et al. Truncated bFGF-mediated cationic liposomal paclitaxel for tumor-targeted drug delivery: improved pharmacokinetics and biodistribution in tumor-bearing mice. J Pharm Sci. 2011;100(3):1196-1205.
52. Spelios M, Kearns M, Savva M. From gene delivery to gene silencing: plasmid DNA-transfecting cationic lipid 1,3-dimyristoylamidopropane-2-[bis(2-dimethylaminoethane)] carbamate efficiently promotes small interfering RNA-induced RNA interference. Biochemistry. 2010;49(27):5753-5759.
53. Jeong JH, Park TG, Kim SH. Self-assembled and nanostructured siRNA delivery systems. Pharm Res. 2011;28(9):2072-2085.
54. Santel A, Aleku M, Keil O, et al. A novel siRNA-lipoplex technology for RNA interference in the mouse vascular endothelium. Gene Ther. 2006;13(16):1222-1234.
55. Murase Y, Asai T, Katanasaka Y, et al. A novel DDS strategy, "dual-targeting", and its application for antineovascular therapy. Cancer Lett. 2010;287(2):165-171.
56. Osborn L, Hession C, Tizard R, et al. Direct expression cloning of vascular cell adhesion molecule 1, a cytokine-induced endothelial protein that binds to lymphocytes. Cell. 1989;59(6):1203-1211.
57. Voinea M, Manduteanu I, Dragomir E, Capraru M, Simionescu M. Immunoliposomes directed toward VCAM-1 interact specifically with activated endothelial cells - a potential tool for specific drug delivery. Pharm Res. 2005;22(11):1906-1917.
58. Gosk S, Moos T, Gottstein C, Bendas G. VCAM-1 directed immunoli-posomes selectively target tumor vasculature in vivo. Biochim Biophys Acta. 2008;1778(4):854-863.
59. Handsley MM, Edwards DR. Metalloproteinases and their inhibitors in tumor angiogenesis. Int J Cancer. 2005;115(6):849-860.
60. Itoh Y, Seiki M. MT1-MMP: a potent modif ier of pericellular microenvironment. J Cell Physiol. 2006;206(1):1-8.
61. Barbolina MV, Stack MS. Membrane type 1-matrix metalloproteinase: substrate diversity in pericellular proteolysis. Semin Cell Dev Biol. 2008;19(1):24-33.
62. Kondo M, Asai T, Katanasaka Y, et al. Anti-neovascular therapy by liposomal drug targeted to membrane type-1 matrix metalloproteinase. Int J Cancer. 2004;108(2):301-306.
63. Hatakeyama H, Akita H, Ishida E, et al. Tumor targeting of doxorubicin by anti-MT1-MMP antibody-modified PEG liposomes. Int J Pharm. 2007;342(1-2):194-200.
64. Hynes RO. Integrins: versatility, modulation, and signaling in cell adhesion. Cell. 1992;69(1):11-25.
65. Hood JD, Cheresh DA. Role of integrins in cell invasion and migration. Nat Rev Cancer. 2002;2(2):91-100.
66. Serini G, Valdembri D, Bussolino F. Integrins and angiogenesis: a sticky business. Exp Cell Res. 2006;312(5):651-658.
67. Janssen AP, Schiffelers RM, ten Hagen TL, et al. Peptide-targeted PEG-liposomes in anti-angiogenic therapy. Int J Pharm. 2003;254(1): 55-58.
68. Schiffelers RM, Koning GA, ten Hagen TL, et al. Anti-tumor efficacy of tumor vasculature-targeted liposomal doxorubicin. J Control Release. 2003;91(1-2):115-122.
69. Meng S, Su B, Li W, et al. Integrin-targeted paclitaxel nanoliposomes for tumor therapy. Med Oncol. 2011;28(4):1180-1187.
70. Kim S, Bell K, Mousa SA, Varner JA. Regulation of angiogenesis in vivo by ligation of integrin alpha5beta1 with the central cell-binding domain of fibronectin. Am J Pathol. 2000;156(4):1345-1362.
71. Dai W, Yang T, Wang X, Wang J, Zhang X, Zhang Q. PHSCNK-Modified and doxorubicin-loaded liposomes as a dual targeting system to integrin-overexpressing tumor neovasculature and tumor cells. J Drug Target. 2010;18(4):254-263.
72. Hamano N, Negishi Y, Fujisawa A, et al. Modification of the C16Y peptide on nanoparticles is an effective approach to target endothelial and cancer cells via the integrin receptor. Int J Pharm. 2012;428(1-2): 114-117.
73. Kluza E, Jacobs I, Hectors SJ, et al. Dual-targeting of αvβ3 and galectin-1 improves the specificity of paramagnetic/fluorescent liposomes to tumor endothelium in vivo. J Control Release. 2012;158(2): 207-214.
74. Curnis F, Sacchi A, Corti A. Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration. J Clin Invest. 2002;110(4):475-482.
75. Chen Y, Wu JJ, Huang L. Nanoparticles targeted with NGR motif deliver c-myc siRNA and doxorubicin for anticancer therapy. Mol Ther. 2010;18(4):828-834.
76. Pastorino F, Brignole C, Marimpietri D, et al. Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy. Cancer Res. 2003;63(21):7400-7409.
77. Matsui M, Shimizu Y, Kodera Y, Kondo E, Ikehara Y, Nakanishi H. Targeted delivery of oligomannose-coated liposome to the omental micrometastasis by peritoneal macrophages from patients with gastric cancer. Cancer Sci. 2010;101(7):1670-1607.
78. Pouvreau I, Zech JC, Thillaye-Goldenberg B, Naud MC, Van ROoijen N, de Kozak Y. Effect of macrophage depletion by liposomes containing dichloromethylene-diphosphonate on endotoxin-induced uveitis. J Neuroimmunol. 1998;86(2):171-181.
79. Killion JJ, Fidler IJ. Therapy of cancer metastasis by tumoricidal activation of tissue macrophages using liposome-encapsulated immunomodulators. Pharmacol Ther. 1998;78(3):141-154.
80. Nardin A, Lefebvre ML, Labroquère K, Faure O, Abastado JP. Liposomal muramyl tripeptide phosphatidylethanolamine: Targeting and activating macrophages for adjuvant treatment of osteosarcoma. Curr Cancer Drug Targets. 2006;6(2):123-133.
81. Coffelt SB, Hughes R, Lewis CE. Tumor-associated macrophages: effectors of angiogenesis and tumor progression. Biochim Biophys Acta. 2009;1796(1):11-18.
82. Martinez FO, Sica A, Mantovani A, Locati M. Macrophage activation and polarization. Front Biosci. 2008;13:453-461.
83. Banciu M, Metselaar JM, Schiffelers RM, Storm G. Antitumor activity of liposomal prednisolone phosphate depends on the presence of functional tumor-associated macrophages in tumor tissue. Neoplasia. 2008;10(2):108-117.
84. Banciu M, Schiffelers RM, Storm G. Investigation into the role of tumor-associated macrophages in the antitumor activity of Doxil. Pharm Res. 2008;25(8):1948-1955.
85. Laakkonen P, Akerman ME, Biliran H, et al. Antitumor activity of a homing peptide that targets tumor lymphatics and tumor cells. Proc Natl Acad Sci U S A. 2004;101(25):9381-9386.
86. Fogal V, Zhang L, Krajewski S, Ruoslahti E. Mitochondrial/cell-surface protein p32/gC1qR as a molecular target in tumor cells and tumor stroma. Cancer Res. 2008;68(17):7210-7218.
87. Yan Z, Wang F, Wen Z, et al. LyP-1-conjugated PEGylated liposomes: A carrier system for targeted therapy of lymphatic metastatic tumor. J Control Release. 2012;157(1):118-125.
88. Baeten D, Demetter P, Cuvelier CA, et al. Macrophages expressing the scavenger receptor CD163: a link between immune alterations of the gut and synovial inflammation in spondyloarthropathy. J Pathol. 2002; 196(3):343-350.
89. Jensen TO, Schmidt H, Møller HJ, et al. Macrophage markers in serum and tumor have prognostic impact in American Joint Committee on Cancer stage I/II melanoma. J Clin Oncol. 2009;27(20): 3330-3337.
90. Etzerodt A, Maniecki MB, Graversen JH, Møller HJ, Torchilin VP, Moestrup SK. Efficient intracellular drug-targeting of macrophages using stealth liposomes directed to the hemoglobin scavenger receptor CD163. J Control Release. 2012;160(1):72-80.
91. Ikehara Y, Niwa T, Biao L, et al. A carbohydrate recognition-based drug delivery and controlled release system using intraperitoneal macrophages as a cellular vehicle. Cancer Res. 2006;66(17): 8740-8748.
92. Baum P, Müller D, Rüger R, Kontermann RE. Single-chain Fv immunoliposomes for the targeting of fibroblast activation protein-expressing tumor stromal cells. J Drug Target. 2007;15(6):399-406.
93. Sadlonova A, Bowe DB, Novak Z, et al. Identification of molecular distinctions between normal breast-associated fibroblasts and breast cancer-associated fibroblasts. Cancer Microenviron. 2009;2(1):9-21.
94. Xian X, Håkansson J, Ståhlberg A, et al. Pericytes limit tumor cell metastasis. J Clin Invest. 2006;116(3):642-651.
95. Kitadai Y, Sasaki T, Kuwai T, et al. Expression of activated platelet-derived growth factor receptor in stromal cells of human colon carcinomas is associated with metastatic potential. Int J Cancer. 2006;119(11):2567-2574.
96. Prakash J, de Jong E, Post E, Gouw AS, Beljaars L, Poelstra K. A novel approach to deliver anticancer drugs to key cell types in tumors using a PDGF receptor binding cyclic peptide containing carrier. J Control Release. 2010;145(2):91-101.
97. Chiquet-Ehrismann R, Chiquet M. Tenascins: regulation and putative functions during pathological stress. J Pathol. 2003;200(4): 488-499.
98. Shao K, Hou Q, Go ML, et al. Sulfatide-tenascin interaction mediates binding to the extracellular matrix and endocytic uptake of liposomes in glioma cells. Cell Mol Life Sci. 2007;64(4):506-515.
99. Achen MG, Mann GB, Stacker SA. Targeting lymphangiogenesis to prevent tumour metastasis. Br J Cancer. 2006;94(10): 1355-1360.
100. Mandriota SJ, Jussila L, Jeltsch M, et al. Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis. EMBO J. 2001;20(4):672-682.
101. Wen J, Fu AF, Chen LJ, et al. Liposomal honokiol inhibits VEGF-D-induced lymphangiogenesis and metastasis in xenograft tumor model. Int J Cancer. 2009;124(11):2709-2718.